This #WomensHistoryMonth, we’re celebrating the remarkable women shaping our future and their invaluable contributions to our industry that inspire us all. Watch as our female colleagues share their vision for the future.

As we wrap up our #AAD2024 day in the life series, join Field Medical Director Greg Stevens as he spends his day engaging with industry professionals and exchanging scientific insights that may inform the next industry breakthroughs.

It's time for a wake-up call on #AtopicDermatitis (AD). See how AD affects more than sleep for both patients and their caregivers: bit.ly/3x7apDo #SkinDeservesMore

Our recent survey awakens awareness of #AtopicDermatitis (AD) and how it affects patients' and caregivers' sleep. And those affected are dreaming of a wider variety in treatments. See why at: bit.ly/3TTdzT5 #SkinDeservesMore

Scratch beyond the surface with our latest survey revealing how #AtopicDermatitis (AD) impacts sleep and quality of life for patients and their caregivers. Explore the insights at: bit.ly/4a7yYyB

When the itch of atopic dermatitis goes untreated, it can overtake daily activities. This #MinorityHealthMonth, it’s more important than ever to recognize the symptoms and disease burden of atopic dermatitis in racial and ethnic minorities. #SkinDeservesMore

Closing the care gap in dermatology starts with addressing the challenges minority communities face. By taking a more inclusive approach to clinical trials and treatment development, we can help more patients achieve healthier skin. #MinorityHealthMonth #SkinDeservesMore

The Food and Drug Administration (FDA) accepts the supplemental New Drug Application for our steroid-free prescription topical therapy in development for adults and children down to 2 years of age with #AtopicDermatitis. #SkinDeservesMore

The relentless itch of #AtopicDermatitis (AD) can severely impact daily life – leading to lack of sleep, lower productivity and increased stress. Learn more about the impact of AD itch on daily routines. #SkinDeservesMore

A wider range of available treatments for #AtopicDermatitis (AD) can help health care practitioners and patients explore therapeutic options that may address symptoms and help provide people living with AD the results they may be looking for. #SkinDeservesMore

This #MemorialDay, we honor and reflect on the veterans who have bravely served over the years. Their courage is an inspiration to us all. Veterans – we salute you.

We’re excited to attend this year’s National Eczema Eczema Expo in Denver, CO, where we’ll learn about new breakthroughs and share insights on eczema management. Make sure to swing by our booth and say hi! #SkinDeservesMore

The Dermavant team hopes everyone has a safe and fun 4th of July!

Today, we honor the dedication, hard work, and achievements of every worker who drives progress and builds our communities, including those who are a part of our Dermavant family. Their contributions continue to make all the difference. Happy Labor Day!

At #FallClinical, we’re presenting new data from our open-label, long-term ADORING 3 clinical trial that highlight the potential of our topical therapy, in clinical development, to be a safe and long-term treatment option for adults and children as young as 2 years old with AD.

#NEWS: Today, Organon announced completing the acquisition of Dermavant Sciences. This step expands Organon’s dermatology capabilities in the U.S. with an additional treatment option. Read the news: bit.ly/4hpOauQ.

Dermavant Sciences has a new home. We are excited to be a part of Organon to help make a better and healthier everyday a reality for patients, families, and communities Follow us at: Organon

Dermavant Sciences is proud to have joined Organon, whose market access capabilities, regulatory expertise, & worldwide commercial reach will help bring treatment options for chronic skin conditions to more patients. Remember to follow us Organon for the latest updates.

Final reminder: the Dermavant Sciences X account is closing at 5 p.m. EST today. Don’t forget to follow us at Organon: Organon. We hope to see you there!